Raphael Pharmaceutical OTC Stock Forecast - Double Exponential Smoothing
| RAPH Stock | 1.40 0.00 0.00% |
Raphael OTC Stock outlook is based on your current time horizon. We recommend always using this module together with an analysis of Raphael Pharmaceutical's historical fundamentals, such as revenue growth or operating cash flow patterns.
The value of RSI of Raphael Pharmaceutical's share price is above 70 as of 27th of January 2026 indicating that the otc stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling Raphael, making its price go up or down. Momentum 73
Buy Stretched
Oversold | Overbought |
It is a matter of debate whether otc price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Raphael Pharmaceutical based on different types of headlines from major news networks to social media. Using Raphael Pharmaceutical hype-based prediction, you can estimate the value of Raphael Pharmaceutical from the perspective of Raphael Pharmaceutical response to recently generated media hype and the effects of current headlines on its competitors.
The Double Exponential Smoothing forecasted value of Raphael Pharmaceutical on the next trading day is expected to be 1.40 with a mean absolute deviation of 0.02 and the sum of the absolute errors of 0.90. Raphael Pharmaceutical after-hype prediction price | USD 1.4 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as otc price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Raphael |
Raphael Pharmaceutical Additional Predictive Modules
Most predictive techniques to examine Raphael price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Raphael using various technical indicators. When you analyze Raphael charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Raphael Pharmaceutical Double Exponential Smoothing Price Forecast For the 28th of January
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Raphael Pharmaceutical on the next trading day is expected to be 1.40 with a mean absolute deviation of 0.02, mean absolute percentage error of 0.01, and the sum of the absolute errors of 0.90.Please note that although there have been many attempts to predict Raphael OTC Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Raphael Pharmaceutical's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Raphael Pharmaceutical OTC Stock Forecast Pattern
| Backtest Raphael Pharmaceutical | Raphael Pharmaceutical Price Prediction | Buy or Sell Advice |
Raphael Pharmaceutical Forecasted Value
In the context of forecasting Raphael Pharmaceutical's OTC Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Raphael Pharmaceutical's downside and upside margins for the forecasting period are 0.01 and 12.81, respectively. We have considered Raphael Pharmaceutical's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Raphael Pharmaceutical otc stock data series using in forecasting. Note that when a statistical model is used to represent Raphael Pharmaceutical otc stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0068 |
| MAD | Mean absolute deviation | 0.0153 |
| MAPE | Mean absolute percentage error | 0.0135 |
| SAE | Sum of the absolute errors | 0.9 |
Predictive Modules for Raphael Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Raphael Pharmaceutical. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Raphael Pharmaceutical After-Hype Price Density Analysis
As far as predicting the price of Raphael Pharmaceutical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Raphael Pharmaceutical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of OTC Stock prices, such as prices of Raphael Pharmaceutical, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Raphael Pharmaceutical Estimiated After-Hype Price Volatility
In the context of predicting Raphael Pharmaceutical's otc stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Raphael Pharmaceutical's historical news coverage. Raphael Pharmaceutical's after-hype downside and upside margins for the prediction period are 0.07 and 23.20, respectively. We have considered Raphael Pharmaceutical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Raphael Pharmaceutical is out of control at this time. Analysis and calculation of next after-hype price of Raphael Pharmaceutical is based on 3 months time horizon.
Raphael Pharmaceutical OTC Stock Price Outlook Analysis
Have you ever been surprised when a price of a OTC Stock such as Raphael Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Raphael Pharmaceutical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the OTC price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Raphael Pharmaceutical, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.98 | 11.41 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.40 | 1.40 | 0.00 |
|
Raphael Pharmaceutical Hype Timeline
Raphael Pharmaceutical is at this time traded for 1.40. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Raphael is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at 0.98%. %. The volatility of related hype on Raphael Pharmaceutical is about 0.0%, with the expected price after the next announcement by competition of 1.40. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be within a week. Check out Historical Fundamental Analysis of Raphael Pharmaceutical to cross-verify your projections.Raphael Pharmaceutical Related Hype Analysis
Having access to credible news sources related to Raphael Pharmaceutical's direct competition is more important than ever and may enhance your ability to predict Raphael Pharmaceutical's future price movements. Getting to know how Raphael Pharmaceutical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Raphael Pharmaceutical may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ISCNF | Isracann Biosciences | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| VYYRF | Voyageur Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.12 | 15.79 | 0.00 | 2,953 | |
| AVCNF | Avicanna | 0.00 | 0 per month | 0.00 | (0.03) | 11.11 | (10.53) | 26.76 | |
| GBLP | Global Pharmatech | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MEDIF | Medipharm Labs Corp | 0.00 | 0 per month | 3.51 | (0.01) | 5.88 | (5.93) | 24.28 | |
| CAAOF | Cannabis One Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EVRRF | Molecule Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CHOOF | Choom Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EMITF | Elbit Imaging | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MYCOF | Mydecine Innovations Group | 0.00 | 0 per month | 0.00 | 0.13 | 20.00 | 0.00 | 3,203 |
Other Forecasting Options for Raphael Pharmaceutical
For every potential investor in Raphael, whether a beginner or expert, Raphael Pharmaceutical's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Raphael OTC Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Raphael. Basic forecasting techniques help filter out the noise by identifying Raphael Pharmaceutical's price trends.Raphael Pharmaceutical Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Raphael Pharmaceutical otc stock to make a market-neutral strategy. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Raphael Pharmaceutical Market Strength Events
Market strength indicators help investors to evaluate how Raphael Pharmaceutical otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Raphael Pharmaceutical shares will generate the highest return on investment. By undertsting and applying Raphael Pharmaceutical otc stock market strength indicators, traders can identify Raphael Pharmaceutical entry and exit signals to maximize returns.
Raphael Pharmaceutical Risk Indicators
The analysis of Raphael Pharmaceutical's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Raphael Pharmaceutical's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting raphael otc stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 6.98 | |||
| Standard Deviation | 21.47 | |||
| Variance | 460.88 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Raphael Pharmaceutical
The number of cover stories for Raphael Pharmaceutical depends on current market conditions and Raphael Pharmaceutical's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Raphael Pharmaceutical is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Raphael Pharmaceutical's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.